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Introduction: Colorectal cancer is one of the most frequently diagnosed malignancies and a 
common cause of cancer-related mortality. The aim of this study was to develop and validate 
a clinical predictive model for 1-year mortality among patients with colon cancer who survive 
for at least 30 days after surgery.
Methods: Patients diagnosed with colon cancer who had surgery for the first time and who 
survived 30 days after the surgery were selected prospectively. The outcome was mortality 
within 1 year. Random forest, genetic algorithms and classification and regression trees were 
combined in order to identify the variables and partition points that optimally classify patients 
by risk of mortality. The resulting decision tree was categorized into four risk categories. Split-
sample and bootstrap validation were performed. ClinicalTrials.gov Identifier: NCT02488161.
Results: A total of 1945 patients were enrolled in the study. The variables identified as the main 
predictors of 1-year mortality were presence of residual tumor, American Society of Anesthe-
siologists Physical Status Classification System risk score, pathologic tumor staging, Charlson 
Comorbidity Index, intraoperative complications, adjuvant chemotherapy and recurrence of 
tumor. The model was internally validated; area under the receiver operating characteristic curve 
(AUC) was 0.896 in the derivation sample and 0.835 in the validation sample. Risk categorization 
leads to AUC values of 0.875 and 0.832 in the derivation and validation samples, respectively. 
Optimal cut-off point of estimated risk had a sensitivity of 0.889 and a specificity of 0.758.
Conclusion: The decision tree was a simple, interpretable, valid and accurate prediction rule 
of 1-year mortality among colon cancer patients who survived for at least 30 days after surgery.
Keywords: clinical prediction rules, colonic neoplasms, colorectal surgery, tree-based methods, 
prediction model, 1-year-mortality
Introduction
Currently, colorectal cancer is among the most common cancers1–3 with high incidence 
and mortality rates, despite improved rates of survival during the last few years.4 
Previous scientific work broadly investigated diagnosis and treatment of colorectal 
cancer. However, work on the development of clinical prediction rules for patients with 
colorectal cancer in order to predict adverse events and mortality after surgical treat-
ment needs to be properly validated and translated into easy-to-use tools for clinical 
practice.5–6 Ideally, studies should investigate robust clinical outcomes such as mortality 
and/or complications, in order to identify related factors, as well as patient-reported 
outcomes, such as health-related quality of life, and their determinants of change.7–9 
Some predictive scores of short-term evolution outcomes, 30 days, have been devel-
oped, such as the various versions of the Physiological and Operative Severity Score 
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for the enUmeration of Mortality and morbidity (POSSUM) 
 scoring,10–12 although most of them are not properly validated 
in most settings. Furthermore, to our knowledge, there are 
no validated prediction models for medium-term follow-up, 
1–2 years, on colorectal cancer outcomes, a period during 
which the majority of adverse outcomes after treatment and/
or surgery are observed.13
Classification and regression trees (CART) have been 
used extensively as an alternative to the classic linear 
and additive prediction models. Results are presented in 
tree form of a decision rule with a hierarchical sequential 
structure that can be easily understood and applied in clini-
cal practice. CART models have been used previously for 
prognosis classification in cancer and other diseases.14–16 
Various studies have performed CART analysis in colorectal 
cancer patients to search for biomarkers highly predic-
tive of response to therapy in order to select patients for 
 treatment17–19 or to select genes for phenotypic classifica-
tion.20,21 However, to our knowledge, there are no validated 
prediction models, including CART models, for medium-
term mortality among patients with colon cancer. Other 
relatively modern modeling techniques, known as machine 
learning methods, which include random forests (RF), 
neural networks (NN) or support vector machine (SVM), 
have received increasing attention in medical research as 
they may potentially provide more accurate results.22–24 
In 2011, Manilich et al developed a prognostic model for 
colorectal cancer including several outcomes to investigate 
competing-risk survival for 5 years using RF methods; 
this model was based on multiple clinical factors with the 
objective of evaluating the accuracy of patient staging solely 
based on the tumor–node–metastasis (TNM).25 Moreover, 
several machine learning techniques have been ensembled 
into a single algorithm that provides a prediction rule with 
the best mean-squared error (MSE).26 However, the use of 
these complex classifying techniques is not common in 
clinical research for predictive purposes.
The Results and Health Services Research in Colorectal 
Cancer (CCR-CARESS) project is a prospective cohort study 
that recruited incident colorectal cancer patients receiving 
surgical treatment and that followed them during 5 years. 
It is, therefore, an appropriate study design for developing 
clinical predictive rules. In line with one of the main purposes 
of the CCR-CARESS project, the aim of this study was to 
combine RF and CART modeling approaches in order to 
develop and validate a clinical predictive model for 1-year 
mortality among patients with colon cancer who survive for 
at least 30 days after receipt of a surgical intervention. The 
objectives were first to identify clinical factors that most 
accurately predict 1-year mortality among this group of 
patients post surgery, and second, to develop and validate a 
clinically applicable predictive rule.
Methods
Study design
The CCR-CARESS prospective observational cohort is 
a multicenter study of patients diagnosed with colorectal 
cancer who had undergone surgical interventions that were 
carried out between June 2010 and December 2012 in 22 
public hospitals in Spain. Those hospitals represented nine 
provinces from six regions in Spain and all of them operate 
under the Spanish National Health Service. Patients have a 
follow-up period of up to 5 years after surgery.
The design and purposes of the study have been thor-
oughly described previously.27
Patient selection
Patients were eligible for the CCR-CARESS study if they 
were diagnosed with colon cancer (up to 15 cm above the anal 
margin) or rectum cancer (between the anal margin and 15 cm 
above it), and received curative or palliative surgery for the first 
time. Patients were identified from the surgical waiting lists 
of each hospital and were invited to participate during a clini-
cal visit or by letter. Colorectal cancer diagnosis was mainly 
based on anatomopathologic diagnosis after a biopsy by colo-
noscopy.28–30 Exclusion criteria were in situ cancer, inoperable 
tumor, severe mental or physical pathologies that could prevent 
patients from responding to the questionnaires, and terminal 
illness. Patients were informed of the study and they were 
asked to sign an informed consent before participating. In the 
current study, patients were considered if they had a diagnosis 
of colon cancer and survived 30 days after the intervention.
Variable collection
Qualified and trained reviewers collected clinical data from 
the medical records, employing data collection forms and an 
instructions manual to ensure consistency among hospitals 
and reviewers. Baseline data collected upon hospital admis-
sion included sociodemographic, clinical (including onset of 
symptoms, habits, personal and family background, comor-
bidities, diagnostic tests and preintervention treatments), 
preoperative (including laboratory parameters, tumor mark-
ers, diagnostic tests and preintervention clinical staging) and 
pathology information; and outpatient anesthesia information 
on the surgical intervention (American Society of Anesthe-
siologists Physical Status Classification System [ASA] risk 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
22
7.
89
.2
1 
on
 2
8-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
237
Prediction of 1-year mortality for colon cancer
score31). Data related to the hospital admission included 
information on the surgical intervention, anatomic pathology 
data, length of stay, presence or degree of complications and 
data related to the remaining days of admission (including 
the presence of complications, the need for reintervention or 
death). The Charlson Comorbidity Index (CCI) was calcu-
lated based on general comorbidities.32 TNM classification 
was assessed according to the 7th Edition of the American 
Joint Committee on Cancer,29 and focused on the prein-
tervention/clinical TNM (cTNM) and the histopathologic 
report for TNM (histopathologic tumor–node–metastasis 
[pTNM]). For the final-stage grouping, pTNM was grouped 
into three categories: 0–II, III and IV. The surgical margins 
were examined for the presence of residual tumor, which was 
described using the residual tumor (R) classification: R0 was 
microscopically free proximal and distal margins; R1 was 
microscopically involved margins and R2 was macroscopic 
residual cancer.29 Lymph node ratio (LNR), defined as the 
ratio of tumor-infiltrated lymph nodes to total number of 
resected lymph nodes, was calculated and categorized as 
suggested by Rosenberg et al.33 Data on laboratory results, 
diagnostic tests, presence of complications, readmissions, 
reintervention or death were collected up to 30 days after 
surgery. Finally, information was collected throughout 
the year, regarding the need for radiation therapy and/or 
chemotherapy, including treatment schedule, cycles, com-
plications and supportive care required; laboratory results 
and diagnostic tests performed; presence of complications; 
tumor recurrence; readmission or reintervention and death.
Further information, which includes the full study pro-
tocol, has been published elsewhere.27
Outcome measures
The primary outcome was mortality within 1 year of surgery 
among those who survived for at least 30 days after surgery. 
Vital status was established by reviewing medical records and 
examining the hospital databases and National Death Index. 
Deaths were considered confirmed if the name, gender, and 
date of birth and identity card on the record matched those 
of the participant.
Statistical analysis
The study sample was randomly divided into a derivation 
sample (50%) and a validation sample (50%). Both samples 
were described using means and SDs for continuous variables 
and as frequencies and percentages for categorical variables. 
Differences between the derivation and the validation samples 
were tested for the distribution of each variable using the 
two-sample Student’s t-test for continuous variables and 
the chi-square test for categorical variables; nonparametric 
methods were used when necessary. The same methods were 
used to test univariate associations between predictors and 
1-year mortality.
When a missing observation was observed for any 
recorded symptom or complication, it was assumed to be 
asymptomatic or that no complication occurred. When 
pTNM was fully unobserved, it was replaced by the analo-
gous cTNM. Any other unrecorded or unobserved value was 
considered as a missing value. Frequency and percentage of 
missing values were reported for each variable.
Various tree-based methods were used in order to identify 
the variables and partition points that optimally classified 
patients by risk of mortality. First, the best predictors were 
selected using RF methods for the whole sample; 1000 trees 
were used in the RF model. Importance for each variable in 
the model was measured as the mean decreases in accuracy 
(error rate) and in node impurity (Gini Index).34 In addition, 
categorization of continuous variables or new encoding of 
categorical variables was controlled during the modeling 
phase in order to avoid the overimportance of categorical 
variables that could occur in tree-based models.34 Therefore, 
as to optimally categorize continuous predictors, such as 
hemoglobin or hematocrit levels, cut-off points were selected 
using genetic algorithms.35 The final decision tree based on 
a simple recursive partitioning algorithm was created in the 
derivation sample to identify 1-year mortality risk factors 
with the highest discriminative power, including the predic-
tors identified by the RF as most important. To internally 
validate the risk of 1-year mortality derived from the decision 
tree, we used bootstrap resampling with N=2000 repetitions 
and estimated 95% confidence interval (CI).36 We report the 
median of these 2000 repetitions as the parameter estimate 
and the 2.5 and 97.5 percentiles as the 95% CI. Validation 
sample was solely used for evaluating the performance of the 
final tree derived. The MSE was calculated in the validation 
sample in order to evaluate the magnitude of the differences 
between the observed and predicted probabilities of mortality.
To make the tree more user friendly, we simplified the 
resulting algorithm into a manageable number of risk classes 
based mainly on the estimated risk of 1-year mortality. We 
applied the risk classification derived from the derivation 
sample to the validation sample. Model discrimination of the 
tree and the risk categories was assessed by the area under the 
receiver operating characteristic (ROC) curve (AUC) and esti-
mated risk dichotomization for optimal sensitivity–specificity 
combination.37 The Cochran–Armitage trending statistic was 
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performed to assess whether classification provided by the tree 
could differentiate low-risk patients from high-risk patients in 
a fashion of graded response based on the level of risk present.
Multiple logistic regression (LR) was also fitted to data 
in the derivation sample. The same covariates that were 
previously selected by the recursive partitioning algorithm 
were included in the LR model. Firth’s penalized maximum 
likelihood estimation was used when necessary to reduce 
bias in the parameter estimates when data separation 
occurred because of the small number of events.38,39 The lin-
ear predictor function obtained from the derivation sample 
was applied to the validation sample. Categorization of the 
predicted risk of mortality was also performed for the LR 
model using the same criteria as before. Model discrimina-
tion of the LR model was evaluated in the same way as we 
did for the decision tree. Comparison of the discrimination 
ability between the decision tree and the LR model was 
performed using a bootstrap test with N=2000 repetitions 
to compare AUCs obtained from two ROC curves.40,41
Effects were considered statistically significant at a=0.05. 
Statistical analyses were performed using SAS for Windows© 
version 9.1 and R version 3.4.
Ethics approval and consent to 
participate
Patients were informed of the CCR-CARESS study objectives, 
invited to voluntarily participate and were included in the study 
sequentially. All of them signed a written informed consent to 
participate in the study. The Institutional Review Boards of the 
participating hospitals approved this project. In particular, the 
Clinical Research Ethics Committee of the Basque Country 
(CEIC-E), the Clinical Research Ethics Committee of the 
Hospital Galdakao-Usansolo, the Clinical Research Ethics 
Committee of the Hospital Txagorritxu, the Clinical Research 
Figure 1 Variable importance for the top 30 predictors of 1-year mortality selected by the random forest.
Abbreviations: ASA, American Society of Anesthesiologists; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CRC, colon or rectum cancer; ICU, intensive care 
unit; pTNM, histopathologic tumor–node–metastasis.
Variables
Residual tumor
Surgical approach
Complications at ICU/Reanimation Unit
Medical complications up to 30 days
Aggravating pathology
Infectious complications up to 30 days
Past history of CRC
Cancer complications up to 30 days
Surgical complications up to 30 days
Mean Decrease Gini Index
Admission to ICU/Reanimation Unit
Tumor localization
Recurrence up to 1 year
Adjuvant chemotherapy
Readmission up to 30 days
Hematocrit level
ASA
Gender
Intraoperative complications
Invasion of adjacent organs
K-ras
CA 19-9
Charlson Comorbidity Index
Smoking habit
Surgical severity
Age
Complications during hospitalization
pTNM stage
Hemoglobin
CEA
Reintervention during hospitalization
19.5
13.3
3.0
2.5
2.4
2.1
1.9
1.2
1.1
6.4
6.0
5.8
5.5
5.5
5.3
5.0
5.0
4.3
4.0
6.1
6.3
10.2
7.5
7.5
7.0
6.5
11.3
4.0
3.7
3.0
Importance
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Ethics Committee of the Área Sanitaria de Gipuzkoa, the 
Clinical Research Ethics Committee of the Hospital Basurto, 
the Clinical Research Ethics Committee of the Hospital Uni-
versitario La Paz, the Clinical Research Ethics Committee of 
the Hospital Universitario Fundación Alcorcón, the Clinical 
Research Ethics Committee of the Hospital Clínico San Car-
los, the Regional Committee of Clinical Trials of Andalucía 
(Sevilla), the Clinical Research Ethics Committee of the 
Agencia Sanitaria Costa del Sol, the Clinical Research Ethics 
Committee of the Parc Taulí Sabadell-University Hospital, the 
Clinical Research Ethics Committee of the Hospital del Mar 
and the Clinical Research Ethics Committee Fundació Unio 
Catalana d’Hospitals approved the study.
Results
A total of 1945 patients were enrolled in the study: 981 (50%) 
and 964 (50%) were randomized to the derivation and the 
validation samples, respectively. Differences between the two 
samples were not statistically significant (P>0.05), except for 
surgical complications up to 30 days after surgery (P=0.049). 
Table S1 shows these results in more detail.
Figure 1 shows the importance scores for the top 30 
predictors used in the RF model for 1-year mortality. Asso-
ciation between predictors and 1-year mortality is shown 
using univariate analysis in the derivation sample (Table 1). 
Significant variables from univariate analysis and the top 30 
predictors provided by the RF model were included in the 
splitting process for building the classification tree using 
CART modeling in order to investigate 1-year mortality 
(Figure 2). Variables selected using the CART model were 
the presence of residual tumor (R0, R1 vs R2), ASA risk 
score categorized into two groups (I–III vs IV), pTNM, 
CCI, intraoperative complications, chemotherapy treat-
ment after surgery and tumor recurrence during the 1-year 
period. The mortality rate was <5% in all those patients 
with residual tumors classified as R0 or R1, ASA below 
IV, no intraoperative complications and pTNM less than or 
equal to III, with the exception of those in a pTNM III stage 
without adjuvant chemotherapy. Generally, mortality rates 
were >10% among patients with residual tumors classified 
as R0 or R1 and patients with an ASA risk score of IV, with 
intraoperative complications or with pTNM between III or 
IV. Among patients with residual tumors classified as R2, 
mortality rates were >35%. MSE of the classification tree 
in the validation sample was 0.0026.
The ROC curve of predicted 1-year mortality for the 
CART in the derivation and validation samples is shown 
in Figure 3 along with the cut-off point of estimated risk 
dichotomization for the optimal sensitivity–specificity com-
bination for the derivation sample. The AUC of the CART 
model was 0.896 (95% CI: 0.856, 0.936) and 0.835 (95% 
CI: 0.776, 0.895) in the derivation and validation samples, 
respectively. More detailed results on the internal bootstrap 
validation of the CART analysis are shown in the additional 
material (Figure S1; Table S2).
The LR model provided AUC estimates of 0.883 (95% 
CI: 0.834, 0.933) and 0.817 (95% CI: 0.752, 0.882) in the 
derivation and validation samples, respectively. Difference 
between AUCs obtained from the CART and the LR was not 
statistically significant in any of the two subsamples.
Using data from the derivation sample, the CART cre-
ated four 1-year mortality risk classes: low (<0.03), medium 
(≥0.03 and <0.1), high (≥0.1 and <0.2) and very high (≥0.2). 
The AUC provided by the stratified risk categories in the 
derivation sample was 0.875 (95% CI: 0.823, 0.926). This 
risk classification was validated in the validation sample 
with AUC=0.832 (95% CI: 0.777, 0.888) (Table 2). The 
Cochran–Armitage test showed a statistically significant 
trend in both samples (P<0.0001). The cut-off point for 
dichotomization of estimated mortality risk investigating the 
optimal sensitivity– specificity combination in the derivation 
sample was achieved at point 0.03, leading to a sensitivity of 
0.889 and a specificity of 0.758 for risk of mortality at 1 year.
Risk of mortality predicted by the LR model was also 
categorized, using the same criteria as that for the CART. The 
AUCs for the stratified risk classification obtained from the 
LR model were 0.869 (95% CI: 0.809, 0.929) in the derivation 
sample and 0.817 (95% CI: 0.757, 0.878) in the validation 
sample. Comparison between the AUCs obtained with the 
stratified risk categories from the CART and the LR model 
provided no statistically significant differences.
Discussion
In the current study, this combination of different statistical 
techniques has enabled us to obtain a simple and easy-to-use 
decision tree with obtainable variables that are routinely used 
in daily clinical practice. The tree was obtained from a large 
prospective cohort of patients who underwent surgery for 
colon cancer and were followed for 1-year post surgery. The 
presence of residual tumors (based on R classification) was 
the first variable detected using the tree that was associated 
with mortality within 1 year for patients with colon cancer 
who survived for at least 30 days after surgery. The following 
branches included the ASA risk score, intraoperative com-
plications, pTNM stage, adjuvant chemotherapy, recurrence 
of the tumor in 1 year and CCI score.
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Table 1 Univariate relation of explanatory variables and 1-year mortality in the derivation sample is shown
Variables Missing One-year mortality for up to  
30 days survivors
P-valuea
Yes (n=50) No (n=931)
Before surgery
Gender –
Male 30 (4.9) 582 (95.1) 0.721
Female 20 (5.4) 349 (94.6)
Ageb 2 73.7 (10.5) 68.7 (10.7) 0.001
Smoking habit 10
Smoker 26 (5.6) 442 (94.4) 0.776
Former smoker 5 (4.0) 120 (96.0)
Nonsmoker 19 (7.0) 359 (95.0)
Charlson Comorbidity Indexb – 3.9 (2.2) 2.9 (1.3) 0.002
≤2 18 (3.5) 493 (96.5) 0.02
>2 32 (6.8) 438 (93.2)
Past history of CRC –
No 46 (5.1) 855 (94.9) 0.967
Yes 4 (5.0) 76 (95.0)
CEA 5
No 14 (6.5) 204 (93.6) 0.324
Yes 36 (4.8) 722 (95.2)
CA 19-9 16
No 31 (5.5) 537 (94.5) 0.643
Yes 19 (4.8) 378 (95.2)
Hemoglobinb 16 14.4 (19.6) 14.7 (15.7) 0.914
Hematocritb 28 34.4 (8.5) 37.4 (14.4) 0.029
ASA 27
I, II and III 41 (4.5) 875 (95.5) <0.001
IV 8 (21.0) 30 (79.0)
Hospitalization
Aggravating pathologyc –
No 41 (4.5) 875 (95.5) 0.004
Yes 9 (13.9) 56 (86.1)
Surgical approach 1
Open surgery 24 (5.8) 393 (94.2) 0.631
Laparoscopy 13 (5.6) 218 (94.4)
Both 11 (3.7) 286 (96.3)
Others 2 (5.7) 33 (94.3)
Surgical severity 1
Minor 0 0 <0.001
Moderate 3 (42.9) 4 (57.1)
Major 35 (4.7) 708 (95.3)
Complex major 12 (5.2) 218 (94.8)
Tumor site –
Right-transverse side 27 (9.5) 388 (93.5) 0.086
Left 23 (4.1) 543 (95.9)
Adjacent organ invasion –
0 36 (4.1) 844 (95.9) <0.001
1 8 (9.6) 75 (90.4)
>1 6 (33.3) 12 (66.7)
Lymph node ratiob 79 0.24 (0.28) 0.08 (0.16) <0.001
<0.17 24 (3.1) 748 (96.6) <0.001
[0.17–1.41) 9 (8.7) 95 (91.4)
[1.41–0.69] 7 (15.9) 37 (84.1)
>0.69 3 (17.7) 14 (82.4)
Intraoperative complications –
No 35 (3.9) 865 (96.1) <0.001
Yes 15 (18.5) 66 (81.5)
(Continued)
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Variables Missing One-year mortality for up to  
30 days survivors
P-valuea
Yes (n=50) No (n=931)
pTNM stage 3
0, I, II 13 (2.3) 561 (97.7) <0.001
III 20 (6.4) 295 (93.6)
IV 16 (18.2) 73 (82.0)
Residual tumor 40
R0 33 (3.8) 849 (96.3) <0.001
R1 3 (9.1) 30 (90.9)
R2 11 (42.3) 15 (57.7)
K-ras –
Not done 36 (4.7) 737 (95.3) 0.010
No mutation 7 (4.1) 165 (95.4)
Mutation 5 (16.7) 25 (83.3)
Complications after surgery –
No 22 (3.9) 548 (96.1) 0.038
Yes 28 (6.8) 383 (93.2)
Reintervention –
No 47 (5.2) 858 (94.8) 0.635
Yes 3 (4.0) 73 (96.1)
Admission at reanimation/ICU –
No 30 (3.9) 734 (96.1) 0.002
Yes 20 (9.2) 197 (90.8)
Complications at reanimation/ICU –
No 45 (5.1) 839 (94.9) 0.978
Yes 5 (5.2) 92 (94.8)
Up to 30 days after surgery
Cancer complications –
No 49 (5.0) 930 (95.0) 0.100
Yes 1 (50.0) 1 (50.0)
Medical complications –
No 44 (4.6) 906 (95.4) 0.004
Yes 6 (19.4) 25 (80.6)
Surgical complications –
No 49 (5.2) 898 (94.8) 0.561
Yes 1 (2.9) 33 (97.1)
Infectious complications –
No 48 (5.3) 862 (94.7) 0.573
Yes 2 (2.8) 69 (97.2)
Readmission –
No 44 (4.9) 862 (95.1) 0.266
Yes 6 (8.0) 69 (92.0)
One-year follow-up
Adjuvant chemotherapy 7
No 26 (3.3) 519 (95.2) 0.801
Yes 19 (4.4) 410 (95.6)
Readmission –
No 22 (2.9) 749 (97.1) <0.001
Yes 28 (13.3) 182 (86.7)
Recurrence of the tumor –
No 31 (3.6) 838 (96.4) <0.001
Yes 19 (17.0) 93 (83.0)
Notes: Frequency and percentage are shown for all categorical variables. aResult provided by the Student’s t-test for continuous variables and the chi-square test for 
categorical variables, nonparametric methods were used when necessary. bMean and SD are shown for continuous variables. cAggravating pathology is defined as having one 
of the following diagnoses: occlusion, perforation, fistula, abscess, bleeding and diffuse location peritonitis.
Abbreviations: ASA, American Society of Anesthesiologists; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CRC, colon or rectum cancer; ICU, intensive care 
unit; pTNM, histopathologic tumor–node–metastasis.
Table 1 (Continued)
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Figure 2 Results of the CART analysis for 1-year mortality in the derivation sample.
Notes: Each branch shows the classification variable and each node shows the number of subjects and the estimated probability of 1-year mortality on that node. Final nodes 
are in bold using different line types for stratified risk groups: low (dotted), medium (dashed), high (dotted dash) and very high (solid). Application to the validation sample is 
shown below each node in light gray-colored boxes.
Abbreviations: ASA, American Society of Anesthesiologists; CART, classification and regression trees; CCI, Charlson Comorbidity Index; Chem, adjuvant chemotherapy; 
IntraCom, intraoperative complications; pTNM, histopathologic tumor–node–metastasis; R1y, recurrence of the tumor; ResTum, residual tumor.
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Figure 3 ROC curve for predicted 1-year mortality by the CART analyses.
Notes: Solid line applies for derivation sample and dashed line for validation sample. AUC=0.896 and 95% CI is (0.856, 0.936) for derivation sample and AUC=0.835 and 95% 
CI is (0.776, 0.895) for validation sample. The cut-off point of estimated 1-year mortality risk dichotomization for optimal sensitivity–specificity combination for derivation 
sample is shown with the corresponding specificity and sensitivity values.
Abbreviations: AUC, area under the receiver operating characteristic curve; CART, classification and regression trees; CI, confidence interval; ROC, receiver operating 
characteristic.
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As regards the comparison of our results with other 
results reported in the literature, there are other studies that 
conclude that the presence of residual tumor after surgery 
could be interpreted as a surrogate of the severity of the dis-
ease, as well as an indicator of surgery effectiveness.42 Other 
predictors identified of 1-year mortality were related to the 
general condition of patient before surgery, such as ASA and 
comorbidities (based on the CCI), or directly related to the 
severity of the disease as determined using the pTNM stage. 
Comorbidities, in conjunction with age, have been previously 
reported to have an impact on mortality,13,43,44 as well as the 
ASA score.25,45 Previous studies have determined that the 
severity of the colon cancer, as measured by the TNM stage, 
lymph node status, number of lymph nodes positive for tumor, 
or depth of primary tumor penetration, is a predictor of 1-year 
mortality.46 With regard to adjuvant chemotherapy, several tree 
nodes showed that it was a predictor of 1-year mortality; this 
same finding has been demonstrated in other studies.47 Finally, 
variables related to the condition of the patient during and after 
surgery, such as intraoperative complications and recurrence 
of the tumor in 1 year, are also present in the tree and have 
been previously identified as predictors in other studies.42,48
Tree-based methods, such as RF and CART, are advanta-
geous compared to linear and additive models, such as regres-
sion models. Tree-based methods do not require parametric 
specification of the relationship between the predictors and 
the outcome, whereas regression methods do require. It basi-
cally means that while regression models are fitted based on 
an equation that defines how in theory the predictors and 
the outcome are related, tree-based models do not assume 
any predefined relationship between the variables. Thanks 
to this feature of tree-based models, these allow for the 
natural incorporation of complex interactions and relation-
ships between covariates, aside from what is already known, 
and various competing and inter-related variables can be 
explored simultaneously. Generally, importance of predic-
tors in a univariate regression framework and in a tree-based 
framework could differ considerably, as occurs in our study, 
probably due to the interaction effects. The final tree showed, 
for instance, an interaction effect between adjuvant chemo-
therapy and pTNM stage, with significant splits depending 
on adjuvant chemotherapy for pTNM stage III when there 
were not intraoperative complications and for pTNM stages 
III and IV in the presence of intraoperative complications, 
for patients with ASA I, II or III and residual tumor classified 
as R0 or R1, while the same split was not present for other 
combinations of the same variables. Moreover, in practice, 
the main advantage of tree-based methods is that the result 
provided in a decision tree form can be easily interpreted by 
clinicians and researchers and somehow mimics the clinical 
practice in the decision-making process. RF is based on an 
algorithm that uses bootstrapping in conjunction with CART, 
thereby randomly selecting individuals and predictors from 
the original sample in an iterative way, and protecting the 
model from overfitting. RF is computationally more efficient 
than other tree-based methods, such as simple CART models, 
and it is robust to a noisy response.34 RF allowed us to select 
the most important variables to be incorporated into the 
tree. Encoding of categorical variables is an important issue 
during the modeling phase in tree-based methods because 
categorical variables could artificially gain importance over 
the continuous variables.34 Prevention against favoring cat-
egorical predictors with a large number of categories over 
continuous or dichotomous predictors was incorporated in 
the modeling phase. In addition, categorization of some 
predictors, for easy interpretation of the results, has been 
optimized by selecting the optimal number and location of 
cut-off points using a prediction framework based on genetic 
algorithms, recently proposed in the literature.35
One recent publication concludes that modern machine 
learning techniques, such as RF, SVM and NN, showed 
instability and a high optimism even with >200 events per 
Table 2 Distribution of the subjects depending on the estimated risk of 1-year mortality
Derivation sample (981) Validation sample (964)
Risk group No (931) Yes (50) No (893) Yes (71)
Unclassified 60 (92.3) 5 (7.7) 51 (85.0) 9 (15.0)
Low 634 (99.4) 4 (0.6) 594 (98.3) 10 (1.7)
Medium 115 (95.0) 6 (5.0) 130 (95.6) 6 (4.4)
High 71 (85.5) 12 (14.5) 66 (79.5) 17 (20.5)
Very high 51 (68.9) 23 (31.2) 52 (64.2) 29 (35.8)
AUC 0.875 (0.823–0.926) 0.832 (0.777–0.888)
Notes: Estimated mortality rate (P) was categorized and classified as mortality risk as follows: low (P<0.03), medium (0.03≤P<0.1), high (0.1≤P<0.2) and very high (P≥0.2). 
Dashed horizontal line shows the cutoff point for dichotomization of estimated 1-year mortality risk looking for optimal sensitivity–specificity combination in the derivation 
sample, leading to a sensitivity of 0.889 and a specificity of 0.758.
Abbreviation: AUC, area under the receiver operating characteristic curve.
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variable.49 They may need over 10 times as many events per 
variable to achieve a stable validated AUC and a small opti-
mism as the more conventional modeling techniques such as 
LR and CART. These findings imply that such modern tech-
niques should only be used in medical prediction problems 
if very large data sets are available. When we performed RF 
with the whole sample (n=1945), high classification error was 
obtained. However, we relied on results obtained from RF 
with regard to variable importance, and this information was 
retained to significantly reduce the number of predictors to 
be incorporated in order to develop a classification tree using 
CART. In practice, when we look for higher accuracy, most 
of the models become more complex and their interpretation 
becomes more difficult. This is always the tradeoff we make 
when prediction accuracy is the primary goal.34 However, 
the simple result obtained from the CART method provided 
an interpretable tree. Moreover, the split-sample validation 
and the bootstrap internal validation of the CART showed 
stability of the results even with <5% of events in the sample. 
Our final tree was developed with 50 events and 7 variables, 
which is low compared to the usual recommendation for 
binary outcomes of 10 events per predictor.50,51 Hence, the 
results of combining more complex techniques, such as RF 
and genetic algorithms, with more simple approaches, such 
as CART, yield to not only accurate but also valid and stable 
results, as it is shown in our final decision tree. When results 
from the CART and the LR approaches were compared in 
terms of discrimination ability, we have observed that differ-
ence between both methods was not statistically significant. 
Whereas in terms of interpretability, results in a tree form are 
easier to interpret by clinical researchers than the formulae 
provided by regression approaches.
Other studies have used decision trees based on recur-
sive partitioning techniques to predict prognosis in patients 
with cancer.15,52 Radespiel-Tröger et al studied factors that 
predict recurrence of colon cancer after resection using 
tree-based methods.53 Moreover, Manilich et al developed 
an RF prognostic model using clinical and histopathologic 
factors to predict 5-year survival of patients with colorectal 
cancer.25 Their study was, however, limited to patients with 
a complete radical resection of tumor with negative radial or 
distal margins (R0). Investigators concluded that the main 
predictor was LNR, which was not a significant predictor in 
our study. However, other significant variables in that study, 
such as ASA score, tumor stage and treatment, were similar 
to those in our study.
The present study was a large prospective cohort study, 
including 22 hospitals; therefore, there was variability in 
individuals and clinical practice, and the number of vari-
ables that were collected as potential predictors of 1-year 
mortality was high. The whole sample included a 4% of 
patients who underwent palliative resection, who were likely 
to be different on prognostic to those undergoing curative 
resection. However, results excluding these patients were 
very similar to the presented results in terms of prediction 
(correlation coefficient r=0.989). In contrast, from our point 
of view, one value of the present study is to reflect the type 
of patients that appear in hospitals in real life, preserving a 
certain natural heterogeneity. Furthermore, the predictive tree 
was developed following the current structured guidelines 
for the development of prediction models, as detailed in the 
Transparent Reporting of a multivariable prediction model for 
Individual Prognosis Or Diagnosis (TRIPOD) statement.54 In 
combining statistical techniques, we gained validity, accuracy 
and interpretability. Although the predictors identified were 
similar to those in other studies, the simple result obtained 
using the CART method provided an interpretable tree with 
a good predictive ability. Moreover, the internal validation 
of the CART carried out by the bootstrap analysis showed 
stability of the results, even with a low rate of events in the 
sample. Therefore, this prediction rule may help clinicians 
to easily classify patients by prognosis and guide them in the 
follow-up process. Other authors have combined multiple 
machine learning techniques to develop a prediction algo-
rithm with the best MSE.26 However, the result provided by 
that single algorithm is not as intuitive and easy to use as our 
classification tree and therefore, its use in clinical practice 
is more limited than the prediction rule we have proposed.
Given that some of the variables included in the tree, 
such as pTNM, intraoperative complications or adjuvant 
chemotherapy, are only available in the postoperative period, 
main application of this tool would be in the planning of 
the clinical follow-up. Patients with a higher risk of 1-year 
mortality could benefit from a more intensive surveillance 
of their oncologic disease and potential comorbidities and 
complications, while those with a low risk could be scheduled 
to a less intensive follow-up. For more severe patients (ASA 
IV or residual tumor 2), our CART provides information 
about the chances of survival, though the sample size is small. 
Patients with residual tumor 2 seem to have low survival 
expectancy, though chemotherapy increases the likelihood 
of surviving. Among the milder cases (stage 0–II), the result 
of the surgery (residual tumor) marked an important differ-
ence having a high probability of surviving 1 year in those 
with residual tumor 0. In cases with stage III, it helps us to 
see how depending on the result of the surgery as opting for 
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chemotherapy can significantly increase the survival chances. 
This may be able to guide the oncologist about the use of 
more or less aggressive treatments. This tree could also be 
used by health care workers to provide patients with more 
precise prognostic information than that based solely on the 
TNM staging system. Taking into account the high negative 
predictive value of the model, it could be especially useful to 
inform patients classified in the low-risk groups, for which a 
high 1-year survival probability could be reassuring.
Limitations
The limitations that are common in prospective multicenter 
studies with 1 year of follow-up were also present in our 
study. One of these limitations is related to losses to follow-
up, which obviously could be a source of bias, and in our 
study 6% of the patients in the sample were not classified by 
the tree because of missing values in some of the predictive 
variables included in the model. Another limitation we must 
mention is that no inter- or intraobserver reliability studies 
were performed to assess the quality of the data collection 
process. Nevertheless, reviewers were trained at each site and 
were provided with a common manual for the data collection. 
Our study included a few tumor biomarkers, as carcinoem-
bryonic antigen levels and CA 19.9. Prediction ability of the 
models could be increased in the future by including genetic 
and biologic prognostic markers. The influence of variables, 
such as differences in the health care provided to the patients 
or adherence to treatment, was not well documented and 
consequently they were not included in the model; all of these 
factors could have an influence on mortality. Interpretation 
of the stratified risk results in terms of screening must be 
cautious because low positive predictive values (15%–17%) 
could be due to the low mortality rate. This kind of data is 
likely to be clustered within hospitals and it was not taken 
into consideration in the analysis. A mixed-effects approach 
for RF and CART could probably improve the results. This 
kind of methodology has been proposed in the literature for 
continuous outcomes,55 although as far as our knowledge, 
it has not been developed yet for dichotomous responses. 
However, the clustering of patients into hospitals has been 
checked in a generalized mixed-effects model framework, 
showing a negligible effect in this particular data. Finally, 
an important limitation of CART is that including higher-
order interactions without considering the main effects could 
lead to spurious relations between predictors, leading to an 
overestimation of the effect of some predictors. However, 
the use of combined split-sample and bootstrap validation 
techniques provided internally validated results to minimize 
this drawback. Further research is needed in order to validate 
this decision tree using other samples and populations. Such 
studies will provide guidance as the models’ applicability in 
clinical practice and/or what modifications might be needed 
in order to improve its validity.
Conclusion
This clinical prediction rule, which combined RF and CART, 
was a simple, interpretable, valid and accurate prediction 
model for 1-year mortality among colon cancer patients who 
survived for at least 30 days after surgery. This decision tool 
could be provided to clinicians in order to assist in clinical 
decision-making processes.
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Supplementary materials
Table S1 Descriptive statistics for explanatory variables stratified by sample (derivation vs validation)
Variables Missing Randomly split samples P-valuea
Derivation
981 (50.4%)
Validation
964 (49.6%)
Before surgery
Gender –
Male 612 (62.4) 593 (61.5) 0.693
Female 369 (37.6) 371 (38.5)
Ageb 2 68.9 (10.7) 68.9 (10.9) 0.883
Smoking habit 20
Smoker 468 (48.2) 443 (50.6) 0.551
Former smoker 125 (12.9) 114 (12.0)
Nonsmoker 378 (38.9) 357 (37.4)
Charlson Comorbidity Indexb – 2.94 (1.37) 2.84 (1.25) 0.225
≤2 511 (52.1) 524 (54.4) 0.316
>2 470 (47.9) 440 (45.6)
Past history of CRC –
No 901 (91.8) 886 (91.9) 0.614
Yes 80 (8.2) 78 (8.1)
CEA 10
No 218 (22.3) 242 (25.2) 0.134
Yes 758 (77.7) 717 (74.8)
CA 19-9 29
No 568 (58.9) 578 (60.8) 0.392
Yes 397 (41.1) 373 (39.2)
Hemoglobinb 16 14.7 (15.9) 15.3 (18.2) 0.413
Hematocritb 58 37.2 (14.1) 37.3 (19.1) 0.973
ASA 51
I, II and III 916 (96.0) 901 (95.9) 0.855
IV 38 (4.0)
Hospitalization
Aggravating pathologyc –
No 916 (93.4) 879 (91.2) 0.070
Yes 65 (6.6) 85 (8.8)
Surgical approach 2
Open surgery 417 (42.6) 384 (39.9) 0.245
Laparoscopy 231 (23.6) 222 (23.1)
Both 297 (30.3) 330 (34.3)
Others 35 (3.6) 27 (2.8)
Surgical severity 3 0.904
Minor 0 0
Moderate 7 (0.7) 6 (0.6)
Major 743 (75.8) 723 (75.2)
Complex major 230 (23.5) 233 (24.2)
Laterality of the tumor –
Right-transverse side 415 (42.3) 399 (41.4) 0.683
Left 566 (57.7) 565 (58.6)
Adjacent organ invasion –
0 880 (89.7) 861 (89.3) 0.955
1 83 (8.5) 84 (8.7)
>1 18 (1.8) 19 (2.0)
Lymph node ratiob 79 0.09 (0.17) 0.10 (0.19) 0.071
<0.17 772 (82.4) 755 (81.3) 0.447
[0.17–1.41) 104 (11.1) 107 (11.5)
[1.41–0.69] 44 (4.7) 40 (4.3)
>0.69 17 (1.8) 27 (2.9)
Intraoperative complications –
No 900 (91.7) 880 (91.3) 0.718
Yes 81 (8.3) 84 (8.7)
(Continued)
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Variables Missing Randomly split samples P-valuea
Derivation
981 (50.4%)
Validation
964 (49.6%)
pTNM stage 12
0, I and II 574 (58.7) 508 (53.2) 0.051
III 315 (32.2) 346 (36.2)
IV 89 (9.1) 101 (10.6)
Residual tumor 75
R0 882 (93.7) 859 (92.5) 0.558
R1 33 (3.5) 39 (4.2)
R2 26 (2.8) 31 (3.3)
K-ras 12
Not done 773 (79.3) 749 (78.2) 0.732
No mutation 172 (17.6) 174 (18.6)
Mutation 30 (3.1) 35 (3.7)
Complications after surgery –
No 570 (58.1) 582 (60.4) 0.309
Yes 411 (41.9) 382 (39.6)
Reintervention –
No 905 (92.2) 882 (91.5) 0.540
Yes 76 (7.8) 82 (8.5)
Admission at reanimation/ICU –
No 764 (77.9) 753 (78.1) 0.902
Yes 217 (22.1) 211 (21.9)
Complications at reanimation/ICU –
No 884 (90.1) 862 (89.4) 0.614
Yes 97 (9.9) 102 (10.6)
Up to 30 days after surgery
Cancer complications –
No 979 (99.8) 961 (99.7) 0.685
Yes 2 (0.2) 3 (0.3)
Medical complications –
No 950 (96.8) 941 (97.6) 0.299
Yes 31 (3.2) 23 (2.4)
Surgical complications –
No 947 (96.5) 913 (94.7) 0.049
Yes 34 (3.5) 51 (5.3)
Infectious complications –
No 910 (92.8) 910 (94.4) 0.141
Yes 71 (7.2) 54 (5.6)
Readmission –
No 906 (92.4) 888 (92.1) 0.844
Yes 75 (7.7) 76 (7.9)
One year of follow-up
Adjuvant chemotherapy 14
No 545 (56.0) 494 (51.6) 0.056
Yes 429 (44.0) 463 (48.4)
Readmission 3
No 771 (78.6) 740 (77.0) 0.399
Yes 210 (21.4) 221 (23.0)
Recurrence of the tumor 3
No 869 (88.6) 848 (88.2) 0.814
Yes 112 (11.4) 113 (11.8)
Notes: Frequency and percentage are shown for all categorical variables. aResult provided by the two-sample Student’s t-test for continuous variables and the chi-square test 
for categorical variables, nonparametric methods were used when necessary. bMean and SD are shown for continuous variables. cAggravating diagnosis is defined as having 
one of the following diagnoses: occlusion, perforation, fistula, abscess, bleeding and diffuse location peritonitis.
Abbreviations: ASA, American Society of Anesthesiologists; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CRC, colon or rectum cancer; ICU, intensive care 
unit; pTNM, histopathologic tumor–node–metastasis.
Table S1 (Continued)
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Table S2 Internal validation of the CART analysis by bootstrap resampling (N=2000)
Node CART Bootstrap resampling Risk group
N Observed  
mortality risk
Estimated median  
mortality risk
95% CI
1 243 0
− −
Low
2 229 0.0131 0.0131 (0.0040, 0.0300) Low
3 20 0.0500 0.0625 (0.0357, 0.1875) Medium
4 166 0.0060 0.0065 (0.0054, 0.0222) Low
5 27 0.0370 0.0455 (0.0270, 0.1364) Medium
6 40 0.0500 0.0513 (0.0208, 0.1395) Medium
7 10 0.3000 0.3000 (0.1000, 0.6364) Very high
8 60 0.1333 0.1321 (0.0545, 0.2261) High
9 34 0.0588 0.0606 (0.0244, 0.1539) Medium
10 23 0.1739 0.1667 (0.0455, 0.3333) High
11 6 0.5000 0.5000 (0.1667, 1.000) Very high
12 33 0.2121 0.2143 (0.0800, 0.3548) Very high
13 17 0.3529 0.3529 (0.1333, 0.6111) Very high
14 8 0.5000 0.5000 (0.1667, 0.8571) Very high
Note: Estimated median mortality risk, 95% CIs and stratification of risk are shown by node.
Abbreviations: CART, classification and regression trees; CI, confidence interval.
Figure S1 Results of internal validation of the CART analysis by bootstrap resampling (N=2000).
Abbreviation: CART, classification and regression trees.
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